Literature DB >> 27144829

Cancer Stem Cells and Chemoresistance in Glioblastoma Multiform: A Review Article.

Mojdeh Safari, Alireza Khoshnevisan.   

Abstract

Glioblastomamultiforme (GBM) is the most common malignant and aggressive primary tumor of the brain in adults and characterized by a heterogeneous population of cells that are genetically unstable, highly infiltrative, angiogenic, and resistant to chemotherapy. Considerable efforts being devoted to identifying the molecular basis of resistance in GBM and exploring novel therapeutic targets that may improve overall survival. Several independent DNA repair mechanisms that normally safeguard genome integrity can facilitate drug resistance and cancer cell survival by removing chemotherapy- induced adducts. The recent data suggest that the most important mechanism of resistance to alkylating agents is the DNA repair enzyme O6-methylguanine methyltransferase (MGMT). Although, the treatment failure is a result of a number of causes, but currently, it has been demonstrated that a highly tumorigenic subpopulation of cancer cells called glioblastoma stem cells (GSCs) display relative resistance to radiation and chemotherapy. In fact, GBM stem cells express high levels of MGMT and this may account for GBM resistance following chemotherapy. GSCs also contribute to tumor growth through the stimulation of angiogenesis, which has been shown to be a useful therapeutic target in the treatment of recurrent or progressive malignant gliomas. In this review, we summarize the chemoresistance mechanisms of GBMs (to alkylating agents), with a special focus on the role of cancer stem cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 27144829     DOI: jsc.2015.10.4.271

Source DB:  PubMed          Journal:  J Stem Cells        ISSN: 1556-8539


  17 in total

1.  Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.

Authors:  Anna K Kozlowska; Han-Ching Tseng; Kawaljit Kaur; Paytsar Topchyan; Akihito Inagaki; Vickie T Bui; Noriyuki Kasahara; Nicholas Cacalano; Anahid Jewett
Journal:  Cancer Immunol Immunother       Date:  2016-07-20       Impact factor: 6.968

Review 2.  Novel therapies hijack the blood-brain barrier to eradicate glioblastoma cancer stem cells.

Authors:  Raghupathy Vengoji; Moorthy P Ponnusamy; Satyanarayana Rachagani; Sidharth Mahapatra; Surinder K Batra; Nicole Shonka; Muzafar A Macha
Journal:  Carcinogenesis       Date:  2019-03-12       Impact factor: 4.944

3.  Pam3CSK4, a TLR2 ligand, induces differentiation of glioblastoma stem cells and confers susceptibility to temozolomide.

Authors:  Javier Megías; Alba Martínez; Teresa San-Miguel; Rosario Gil-Benso; Lisandra Muñoz-Hidalgo; David Albert-Bellver; Amara Carratalá; Daniel Gozalbo; Concha López-Ginés; María Luisa Gil; Miguel Cerdá-Nicolás
Journal:  Invest New Drugs       Date:  2019-05-11       Impact factor: 3.850

Review 4.  Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy's history, efficacy and application in humans.

Authors:  Keon Mahmoudi; Alexandros Bouras; Dominique Bozec; Robert Ivkov; Constantinos Hadjipanayis
Journal:  Int J Hyperthermia       Date:  2018-02-06       Impact factor: 3.914

Review 5.  Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Authors:  Amandeep Thakur; Chetna Faujdar; Ram Sharma; Sachin Sharma; Basant Malik; Kunal Nepali; Jing Ping Liou
Journal:  J Med Chem       Date:  2022-07-05       Impact factor: 8.039

Review 6.  Cancer stem cell characteristics and their potential as therapeutic targets.

Authors:  Jacqueline R Lim; Josette Mouawad; Olivia K Gorton; William A Bubb; Ann H Kwan
Journal:  Med Oncol       Date:  2021-05-29       Impact factor: 3.064

7.  HIF1α regulates glioma chemosensitivity through the transformation between differentiation and dedifferentiation in various oxygen levels.

Authors:  Pan Wang; Wenwu Wan; Shuanglong Xiong; Junwei Wang; Dewei Zou; Chuan Lan; Shuangjiang Yu; Bin Liao; Hua Feng; Nan Wu
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

8.  The ginsenoside metabolite compound K inhibits growth, migration and stemness of glioblastoma cells.

Authors:  Sanghun Lee; Min Cheol Kwon; Jun-Pil Jang; Jae Kyung Sohng; Hye Jin Jung
Journal:  Int J Oncol       Date:  2017-06-23       Impact factor: 5.650

Review 9.  Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways.

Authors:  Fabliha Ahmed Chowdhury; Md Kamal Hossain; A G M Mostofa; Maruf Mohammad Akbor; Muhammad Shahdaat Bin Sayeed
Journal:  Biomed Res Int       Date:  2018-01-31       Impact factor: 3.411

Review 10.  Emerging Cellular Therapies for Glioblastoma Multiforme.

Authors:  Paul J Choi; R Shane Tubbs; Rod J Oskouian
Journal:  Cureus       Date:  2018-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.